• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

呋罗培南（SY5555或SUN5555）对呼吸道病原体及产β-内酰胺酶细菌的体外活性评估。

Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.

作者信息

Cormican M G, Jones R N

机构信息

Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.

出版信息

J Antimicrob Chemother. 1995 Apr;35(4):535-9. doi: 10.1093/jac/35.4.535.

DOI:10.1093/jac/35.4.535
PMID:7628987
Abstract

Furopenem is a novel orally active penem. In this study, furopenem was highly active in vitro against Streptococcus pneumoniae (MIC90 0.03 mg/L), Haemophilus influenzae (MIC90, 2 mg/L), and Moraxella catarrhalls (MIC90, 0.5 mg/L). Its activity was not reduced by a variety of beta-lactamase enzymes, however beta -lactam resistance by other mechanisms was associated with higher MICs.

摘要

呋罗培南是一种新型口服活性青霉烯类药物。在本研究中，呋罗培南在体外对肺炎链球菌（MIC90为0.03mg/L）、流感嗜血杆菌（MIC90为2mg/L）和卡他莫拉菌（MIC90为0.5mg/L）具有高度活性。其活性不会因多种β-内酰胺酶而降低，然而，其他机制导致的β-内酰胺耐药性与更高的最低抑菌浓度相关。

相似文献

1
Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.呋罗培南（SY5555或SUN5555）对呼吸道病原体及产β-内酰胺酶细菌的体外活性评估。
J Antimicrob Chemother. 1995 Apr;35(4):535-9. doi: 10.1093/jac/35.4.535.
2
In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.对一种新型口服头孢菌素（头孢妥仑）进行体外评估，该评估针对1249株近期临床分离的流感嗜血杆菌、卡他莫拉菌和肺炎链球菌。
Diagn Microbiol Infect Dis. 1998 Aug;31(4):573-8. doi: 10.1016/s0732-8893(98)00044-3.
3
Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.
Int J Antimicrob Agents. 2002 Aug;20(2):76-85. doi: 10.1016/s0924-8579(02)00124-3.
4
In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.头孢丙烯（BMY 28100）和头孢吡肟（BMY 28142）对肺炎链球菌、卡他莫拉菌和流感嗜血杆菌的体外活性，以及流感嗜血杆菌纸片扩散法和稀释药敏试验的临时解释标准。
Diagn Microbiol Infect Dis. 1992 Sep-Oct;15(7):633-40. doi: 10.1016/0732-8893(90)90042-t.
5
In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.中国社区获得性呼吸道感染患者肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外药物敏感性研究：头孢地尼及其他比较药物的活性
Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.
6
Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action.
J Antimicrob Chemother. 1990 Aug;26(2):209-13. doi: 10.1093/jac/26.2.209.
7
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal.1999年在葡萄牙进行的一项多中心研究，该研究针对从社区获得性下呼吸道感染患者中分离出的流感嗜血杆菌、肺炎链球菌和卡他莫拉菌的抗菌药敏情况。
Microb Drug Resist. 2001 Spring;7(1):33-8. doi: 10.1089/107662901750152747.
8
Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.加拿大流感嗜血杆菌、肺炎链球菌和卡他莫拉菌分离株的抗菌药敏性测定。加拿大抗菌研究小组。
J Antimicrob Chemother. 1999 Mar;43 Suppl A:25-30.
9
In-vitro activity of cefodizime against respiratory pathogens.
J Antimicrob Chemother. 1990 Nov;26 Suppl C:9-12. doi: 10.1093/jac/26.suppl_c.9.
10
Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland.芬兰肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的抗菌耐药性不断增加。
J Antimicrob Chemother. 1997 Sep;40(3):387-92. doi: 10.1093/jac/40.3.387.

引用本文的文献

1
Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge.法罗培南在儿童感染治疗中的作用：当前的知识状况
Cureus. 2022 Apr 25;14(4):e24453. doi: 10.7759/cureus.24453. eCollection 2022 Apr.
2
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.口服β-内酰胺类药物法罗培南对美国近期分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的活性。
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
3
In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae.
三氟沙星的体外活性及其对肺炎链球菌青霉素结合蛋白的亲和力。
Antimicrob Agents Chemother. 1998 Jan;42(1):173-5. doi: 10.1128/AAC.42.1.173.
4
Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.新型口服碳青霉烯类药物DZ-2640的母体化合物DU-6681a的抗菌活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1260-8. doi: 10.1128/AAC.41.6.1260.